The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions.
The present invention relates to a compound represented by the general formula (I):
(wherein A represents;
and R1, R2, R3 and R1 each a hydrogen atom or a substituent;
R5 is a substituent; X- is an anion;the symbol:
denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.
or metal catalysts. The synthetic strategy involves anodic cleavage of benzylic C−H to form a carbocation intermediate, which is then trapped with an amine nucleophile leading to C−N bond formation. Key to the success is to include HFIP as a co‐solvent to modulate the oxidation potentials of the alkylbenzene substrate and the aminated product to avoid overoxidation of the latter.
EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE
申请人:ExxonMobil Research and Engineering Company
公开号:US20170158521A1
公开(公告)日:2017-06-08
A novel synthetic crystalline material, EMM-28, can be synthesized in the presence of an organic structure directing agent (Q) selected from one or more of the following dications:
EMM-28 may be used in organic compound conversion reactions and sorptive processes.